TUCSON, Ariz., Aug. 17, 2011 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the SynCardia temporary Total Artificial Heart, announced today that University of Muenster in Germany has successfully bridged its first patient to transplant with the Total Artificial Heart after 89 days of support.
On Jan. 14, 60-year-old Jan Detert was admitted to University of Muenster as an emergency heart attack case (acute myocardial infarction). He was also suffering from a ventricular septal defect, a hole between the left and right ventricles of the heart.
Mr. Detert underwent emergency surgery that included aortocoronary bypass to create a new path to his aorta around a blocked artery, in addition to closing the hole between his heart ventricles using a patch. Two weeks after Mr. Detert's initial recovery from this surgery, he deteriorated when the ventricular septal defect recurred because his tissue had been severely weakened by the heart attack.
"SynCardia's Total Artificial Heart was our only option to save this patient's life," said Prof. Dr. Hans Scheld, Director of the Department of Thoracic and Cardiovascular Surgery. "This case demonstrates that the Total Artificial Heart is capable of bridging a patient with extended myocardial infarction, including ventricular septal defect, to successful heart transplantation."
On Jan. 30, Prof. Dr. T.D.T. Tjan and Prof. Dr. Andreas Hoffmeier implanted Mr. Detert with SynCardia's Total Artificial Heart. His condition stabilized and three months later, on April 29, he became the hospital's first patient to be successfully bridged to transplant with the Total Artificial Heart. Mr. Detert was discharged from the hospital with his new donor heart in June.
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the Total is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. More than 950 implants account for more than 230 patient years of life.
Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end-stage biventricular failure. The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.
In March 2011, Fast Company magazine ranked SynCardia #20 among the World's 50 Most Innovative Companies "for giving mobility to artificial heart recipients." Also in March, the longest running health and wellness series on public television, "Healthy Body, Healthy Mind," produced a 30-minute program featuring SynCardia's Total Artificial Heart. View here
For additional information, please visit: http://www.syncardia.com
or follow SynCardia on Twitter – @SynCardia_News
|SOURCE SynCardia Systems, Inc.|
Copyright©2010 PR Newswire.
All rights reserved